As of May 31, 2018, the registrant had 42,313,552 shares of common stock, $0.0001 par value per share, outstanding.
Unity Biotechnology, Inc. (the "Company" or "we" or "our" or "us") is a biotechnology company engaged in the research and development of therapeutics to extend human healthspan. The Company devotes substantially all of its time and efforts to performing research and development, raising capital and recruiting personnel. The Company is located in Brisbane, California and was incorporated in the state of Delaware in March 2009 under the name Forge, Inc. and operates in one segment. The Company changed its name to Unity Biotechnology, Inc. in January 2015.
On May 7, 2018, the Company closed its initial public offering ("IPO"), of 5,000,000 shares of common stock, at an offering price to the public of $17.00 per share. The Company received net proceeds of approximately $76.1 million, after deducting underwriting discounts, commissions and offering related transaction costs of approximately $8.9 million. In connection with the IPO, all of the Company's outstanding shares of convertible preferred stock were automatically converted into 32,073,149 shares of common stock. In addition, all of our convertible preferred stock warrants were converted into warrants to purchase shares of common stock.
The condensed consolidated financial statements are unaudited and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, necessary for the fair presentation for interim reporting. The results of operations for any interim period are not necessarily indicative of results of operations for any future period. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, the unaudited condensed financial statements should be read in conjunction with the financial statements as of and for the year ended December 31, 2017, which are included in the Company's prospectus related to the Company's initial public offering, filed May 4, 2018 (the "Prospectus"), pursuant to Rule 424 (b) under the Securities Act of 1933, as amended with the SEC.
Reverse Split. Accordingly, all share and per share information presented in the condensed consolidated financial statements herein, and notes thereto, have been retroactively adjusted to reflect the Reverse Split.
The Company has incurred operating losses and has an accumulated deficit as a result of ongoing efforts to develop drug product candidates, including conducting preclinical trials and providing general and administrative support for these operations. The Company had an accumulated deficit of $103.0 million and $86.9 million as of March 31, 2018 and December 31, 2017, respectively. The Company had net losses of $16.1 million and $8.9 million for the three months ended March 31, 2018 and 2017, respectively, and net cash used in operating activities of $11.9 million and $7.9 million for the three months ended March 31, 2018 and 2017, respectively. To date, none of the Company's drug candidates have been approved for sale and therefore the Company has not generated any revenue from contracts with customers. The Company has evaluated and concluded there are no conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a period of one year following the date that these financial statements are issued. Management expects operating losses to continue for the foreseeable future. As a result, the Company will need to raise additional capital. If sufficient funds on acceptable terms are not available when needed, the Company could be required to significantly reduce its operating expenses and delay, reduce the scope of, or eliminate one or more of its development programs. Failure to manage discretionary spending or raise additional financing, as needed, may adversely impact the Company's ability to achieve its intended business objectives.
The condensed financial statements have been prepared in accordance with GAAP, which requires management to make estimates and assumptions that affect the amounts and disclosures reported in the condensed financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company's balance sheets and the amount of expenses and income reported for each of the periods presented are affected by estimates and assumptions, which are used for, but are not limited to, determining the fair value of assets and liabilities, common stock valuation, and stock-based compensation. Actual results could differ from such estimates or assumptions.
Deferred offering costs, consisting of direct incremental legal, accounting, filing and other fees incurred related to the preparation of the IPO, have been capitalized and were offset against proceeds upon completion of the offering in May 2018. As of March 31, 2018, $1.7 million of deferred offering costs were capitalized and included in current assets on the balance sheet. There were no capitalized deferred offering costs at December 31, 2017.
The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the balance sheets that sum to the total of the same amounts shown in the statements of cash flows.
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, marketable securities and contribution receivable. Substantially all of the Company's cash and cash equivalents and restricted cash is deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash deposits. The contribution receivable is unsecured and is concentrated with one third-party organization, and accordingly the Company may be exposed to credit risk. To date, the Company has not experienced any loss related to its contributions receivable.
The Company's investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, restricted cash and marketable securities and issuers of marketable securities to the extent recorded on the balance sheets. As of March 31, 2018, the Company had no off-balance sheet concentrations of credit risk.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This ASU clarifies the definition of a business when evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The guidance is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those years. For all other entities, it is effective for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company is currently evaluating the effect that this guidance will have on its financial statements.
In February 2016, the FASB issued ASU No. 2016-02 ("ASU 2016-02"), Leases (Topic 842), which supersedes the guidance in former ASC 840, Leases. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. For public entities, this standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. For all other entities, this standard is effective for annual reporting periods beginning after December 15, 2019, and interim periods within annual periods beginning after December 15, 2020. Early adoption is permitted. The ASU is expected to impact the Company's financial statements as the Company has certain operating lease arrangements for which the Company is the lessee. Management expects that the adoption of this standard will result in the recognition of an asset for the right to use the leased facility on the Company's balance sheet, as well as the recognition of a liability for the lease payments remaining on the lease. While the Company is currently evaluating the impact of the adoption of this standard on its financial statements, the Company anticipates the recognition of additional assets and corresponding liabilities on its balance sheet related to leases.
In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This guidance makes amendments to the classification and measurement of financial instruments and revises the accounting related to: (1) the classification and measurement of investments in equity securities (except for investments accounted for under the equity method of accounting); and (2) the presentation of certain fair value changes for financial liabilities measured at fair value. In addition, the update also amends certain disclosure requirements associated with the fair value of financial instruments. The guidance is effective for public business entities in 2018. For all other calendar-year entities, it is effective for annual periods beginning in 2019 and interim periods beginning in 2020. Early adoptions of certain amendments within the update are permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its financial statements and related disclosures, including on the Company's cost method investment.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230: Classification of Certain Cash Receipts and Cash Payments). This guidance addresses specific cash flow issues with the objective of reducing the diversity in practice for the treatment of these issues. The areas identified include: debt prepayment or debt extinguishment costs; settlement of zero-coupon debt instruments; contingent consideration payments made after a business combination; proceeds from the settlement of insurance claims; proceeds from the settlement of corporate-owned life insurance policies; distributions received from equity method investees; beneficial interests in securitization transactions; and application of the predominance principle with respect to separately identifiable cash flows. The guidance will generally be applied retrospectively and is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those years. For all other entities, it is effective for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company is currently evaluating the effect that this guidance will have on its financial statements and related disclosures.
On December 22, 2017, the U.S. federal government enacted the Tax Cuts and Jobs Act ("the Act"). The Tax Act contains, among other things, significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% for tax years beginning after December 31, 2017, limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, implementing a territorial tax system, and requiring a mandatory one-time tax on U.S. owned undistributed foreign earnings and profits known as the transition tax. In December 2017, SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118") to address the accounting implications of recently enacted U.S. federal tax reform. SAB 118 allows companies to record provisional amounts during a measurement period not to extend beyond one year of the enactment date to address ongoing guidance and tax interpretations that are expected over the next 12 months. The Company has adopted SAB 118 and currently considers its accounting of the impact of U.S. federal tax reform to be incomplete but continues to make a reasonable estimate of the effects on our existing deferred tax assets. The Company expects to complete the remainder of the analysis within the measurement period in accordance with SAB 118. Adjustments, if any, are not expected to impact the statement of operations and comprehensive loss due to the full valuation allowance on the Company's deferred tax assets.
The Company estimates the fair value of its money market funds, commercial paper, corporate debt securities, asset-backed securities, and U.S. government debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.
There were no transfers within the hierarchy during the three months ended March 31, 2018 and the year ended December 31, 2017.
The grant date fair value of the Company's common stock has been determined by the Company's Board of Directors with the assistance of management and an independent third-party valuation specialist. The grant date fair value of the Company's common stock was determined using valuation methodologies which utilizes certain assumptions including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability (Level 3 inputs). In determining the fair value of the Company's common stock, the methodologies used to estimate the enterprise value of the Company were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation ("AICPA Accounting and Valuation Guide").
At March 31, 2018, the remaining contractual maturities of available-for-sale securities were less than two years. There have been no significant realized gains or losses on available-for-sale securities for the periods presented. Available-for-sale debt securities that were in a continuous loss position but were not deemed to be other than temporarily impaired were immaterial at both March 31, 2018 and December 31, 2017.
In February 2016, the Company entered into a license agreement with a privately held clinical-stage biopharmaceutical company to research, develop, and seek and obtain marketing approval for a licensed compound. In February 2016, in conjunction with this license agreement, the Company also entered into a compound library and option agreement with the same biopharmaceutical company to identify compounds with potential utility in the treatment of age-related conditions other than indications in oncology. This license agreement included contingent consideration of up to 666,670 shares of additional common stock to be issued, up to $70.3 million of milestone payments based on achievement of certain specified clinical development and sales milestone events and tiered royalties in the low-single digits based on sales of licensed products. As of March 31, 2018 and 2017, none of the milestones had been achieved and no royalties were due from the sales of licensed products.
In connection with the compound library and option agreement, the Company received an equity interest for 275,766 ordinary shares of an affiliate of the biopharmaceutical company at an aggregate purchase price of $0.5 million, which represents an insignificant level of ownership in the entity and approximates the fair value of the shares received and has been recorded as a cost method investments in the Company's financial statements. The Company had a commitment to invest an additional $0.5 million in this entity in the future which was exercised in May 2018.
The Company also agreed to provide funding to the biopharmaceutical company for research and development work performed at a cost of up to $2.0 million through February 2020. The research and development expense under the research services agreement was not material for the three months ended March 31, 2018 or 2017.
Under the consolidation guidance, the Company determined that the biopharmaceutical company is a VIE. The Company does not have the power to direct the activities that most significantly affect the economic performance of this entity and as such the Company is not the primary beneficiary and consolidation is not required. As of March 31, 2018 and December 31, 2017, the Company has not provided financial, or other, support to the biopharmaceutical company that was not contractually required.
The Company has entered into license agreements with various research institutions which have provided the Company with rights to patents, and in certain cases, research "know-how" and proprietary research tools to research, develop and commercialize drug candidates. In addition to upfront consideration paid to these various research institutions in either cash or shares of the Company's common stock, the Company may be obligated to pay milestone payments in cash or the issuance of the Company's common stock specific to each agreement on achievement of certain specified clinical development and/or sales events. To date, none of these events had occurred and no milestone or royalty payments have been recognized.
Rent expense for the three months ended March 31, 2018 and 2017 was $0.5 million and $0.5 million, respectively.
The Company indemnifies each of its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company's request in such capacity, as permitted under Delaware law and in accordance with the Company's amended and restated certificate of incorporation and bylaws.
The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity.
The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with the Company's exposure and may enable the Company to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.
In October 2017, the Company issued two promissory notes to an executive officer for $1.6 million and $0.5 million, each with an interest rate of 1.85% per annum. The aggregate principal amount of $2.1 million was used to purchase 625,084 shares of restricted stock. The promissory notes were considered to be non-recourse in substance and accordingly, the shares sold subject to such promissory notes are considered an option for accounting purposes. In April 2018, the Company's board of directors approved the forgiveness of all outstanding principal and accrued interest of the $1.6 million non-recourse promissory note. The non-recourse promissory note outstanding of $0.5 million was repaid on April 4, 2018 in accordance with the terms of the note.
During the three months ended March 31, 2018, the Company issued convertible preferred stock for total proceeds of $3.0 million to shareholders who are considered to be related parties.
In March 2018, the Company amended and restated its certificate of incorporation to, among other things, (i) increase its authorized shares of common stock from 122,000,000 to 140,000,000 shares, (ii) increase its authorized shares of preferred stock from 91,739,149 to 103,283,818 shares, of which 11,544,669 shares are designated as Series C convertible preferred stock, and (iii) set forth the rights, preferences and privileges of the Series C convertible preferred stock. In March 2018, the Company sold 3,590,573 shares of Series C convertible preferred stock at $15.3317 per share for net proceeds of $54.9 million and in April 2018, the Company sold an additional 322,852 shares of Series C convertible preferred stock $15.3317 per share for net proceeds of $5.0 million. .
on a U.S. national securities exchange and at least $30.0 million of gross proceeds at a per share price of not less than the Series C original issue price of $15.3317.
The Company evaluated the other rights, preferences and privileges of each series of convertible preferred stock and concluded that there were either no freestanding derivative instruments or any embedded derivatives requiring bifurcation.
Each share of convertible preferred stock was convertible at the right and option of the stockholder, at any time after the date of issuance, into such number of fully paid and non-assessable shares of common stock on a one for one ratio (1:1 conversion ratio). The Series A-1 conversion price was $0.864 per share, the Series A-2 conversion price was $0.876 per share, the Series B conversion price was $12.125 per share and the Series C conversion price was $15.3317, in each case, subject to certain antidilution adjustments as provided in the Company's amended and restated certificate of incorporation.
Each share of convertible preferred stock was automatically convertible into a fully paid, non-assessable share of common stock at the then-effective conversion rate for such share (i) upon the closing of a firm commitment, underwritten initial public offering of the Company's common stock at an aggregate gross proceeds of not less than $30.0 million and a price per share to the public of not less than $15.3317 per share; or (ii) upon the receipt by the Company of a written request for such conversion from at least 60% of the holders of the convertible preferred stock then outstanding (voting together as a single class and on an as-converted basis), or if later, the effective date for conversion specified in such requests.
(the "Series C Liquidation Preference"). If upon any such liquidation, dissolution or winding up of the Company or a deemed liquidation event, the assets of the Company available for distribution to its stockholders had been insufficient to pay the holders of Series C convertible preferred stock the full amount to which they were entitled, the holders of the Series C convertible preferred stock would have shared ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise have been payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.
In March 2018, the Company's board of directors adopted the Company's 2018 Incentive Award Plan (the "2018 Plan"). The 2018 Plan was approved by the Company's stockholders in April 2018 and became effective on May 2, 2018. The 2018 Plan initially reserved 4,289,936 shares for the issuance of stock options as well as any automatic annual increases in the number of shares of common stock reserved for future issuance under the 2018 Plan. Awards granted under the 2018 Plan expire no later than ten years from the date of grant. For stock options, the option price shall not be less than 100% of the estimated fair value on the day of grant. Options granted typically vest over a four-year period but may be granted with different vesting terms.
In March 2018, the Company's board of directors adopted the Company's 2018 Employee Stock Purchase Plan (the "2018 ESPP"). The 2018 ESPP was approved by the Company's stockholders in April 2018 and became effective on May 2, 2018. The 2018 ESPP reserved 536,242 shares of common stock for issuance pursuant to future awards, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan.
In June 2013, the Company adopted the 2013 Equity Incentive Plan (the "2013 Plan"), which provides for the granting of incentive stock options ("ISOs"), non-statutory stock options ("NSOs") and restricted shares to employees, directors, and consultants at the discretion of management and the Board of Directors. As of March 31, 2018, there were an aggregate of 450,233 shares of common stock authorized for issuance under the 2013 Plan.
The exercise price of an ISO and NSO shall not be less than 100% of the estimated fair value of the shares on the date of grant, and the exercise price of an ISO and NSO granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant. For awards granted between September 2017 and March 2018 with an exercise price of $3.42, a deemed fair value ranging from $3.95 to $5.43 per share was used in calculating stock-based compensation expense, which was determined using management hindsight. Options granted under the 2013 Plan expire no later than 10 years from the date of grant and generally vest over a four-year period but may be granted with different vesting terms. The 2013Plan also provides that unvested options that were not exercised as of an employee's termination date shall revert to the 2013 Plan.
During the three months ended March 31, 2018, the Board of Directors granted performance contingent stock option awards exercisable for 53,575 shares, to certain members of the Company's executive team. These awards had a weighted average exercise price of $3.42 which was based on the fair market value on the grant date, as determined by the Board of Directors, and vest upon the successful achievement of one or more specified performance goals.
The total estimated fair value of employee performance contingent stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model using the same assumptions as the stock options granted to employees with service-based vesting conditions was $0.4 million. As of March 31, 2018, the Company determined that the achievement of the requisite performance conditions was not probable and, as a result, no compensation cost was recognized for the performance contingent awards.
As of March 31, 2018 and 2017, there were 329,498 and 275,922 performance contingent stock option awards outstanding with a total fair value of $0.7 million and $0.3 million respectively. As of March 31, 2018 and 2017, the Company determined that the achievement of the requisite performance conditions was not probable and, as a result, no compensation cost was recognized for these awards.
During the three months ended March 31, 2018, the Board of Directors granted performance and market contingent stock option awards exercisable for 160,727 shares of common stock to certain members of the Company's executive team. These awards had a weighted average exercise price of $3.42, which was based on the fair market value on the grant date, as determined by the Board of Directors. The total estimated grant-date fair value of these options was $0.7 million. Key assumptions in the valuation model included expected volatility, a risk-free interest rate, expected dividend yield, and an expected term unique to the terms of these awards.
based upon (i) the closing of a financing where the Company sells shares of its equity securities to institutional investors at a minimum pre-money valuation, (ii) a change in control with a minimum aggregate proceeds payable to the Company's common stock, or (iii) an initial public offering that becomes effective or an achievement of a minimum market capitalization, as measured by a trailing 30 day volume-weighted average price.
By definition, the market condition in these awards can only be achieved after the performance condition of a liquidity event has been achieved. As such, the requisite service period is based on the estimated period over which the market condition can be achieved. When a performance goal is deemed to be probable of achievement, time-based vesting and recognition of stock-based compensation expense commences. As of March 31, 2018, the Company determined that the achievement of the requisite performance conditions was not probable and, as a result, no compensation cost was recognized for these awards.
As of March 31, 2018 and 2017, there were 454,584 and 360,594 performance and market contingent stock option awards outstanding with a total fair value of $1.0 million and $0.4 million respectively. As of March 31, 2018 and 2017, the Company determined that the achievement of the requisite performance conditions was not probable and, as a result, no compensation cost was recognized for these awards.
Basic net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding for the period. Diluted net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period if the effect is dilutive.
Up to 739,551 shares may be contingently issued, if certain performance conditions are met under our in-licensing agreements.
You should read the following management's discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and notes thereto for the year ended December 31, 2017, included in our prospectus dated May 2, 2018, filed with the U.S. Securities and Exchange Commission (SEC) pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended (the "Prospectus").
We are a biotechnology company engaged in researching and developing therapeutics with a mission to extend human healthspan, the period of time in one's life unburdened by the diseases of aging. Age-associated diseases cause considerable economic, personal and societal burden for individuals, their families and broader communities. Enabled by foundational scientific insights, we have devoted over six years to identifying multiple mechanisms that we believe to be root causes of age-associated disease. We are utilizing these insights to develop a broad portfolio of drug candidates to treat these diseases of aging, and we expect to initiate our first clinical study of one of our lead drug candidates in the second quarter of 2018.
Since the commencement of our operations, we have invested a significant portion of our efforts and financial resources in research and development activities, and we have incurred net losses each year since inception. Our net losses were $16.1 million and $8.9 million for the three months ended March 31, 2018 and 2017, respectively. We do not have any products approved for sale, and we have never generated any revenue from contracts with customers. As of March 31, 2018, we had an accumulated deficit of $103.0 million, and we do not expect positive cash flows from operations in the foreseeable future. We expect to continue to incur net operating losses for at least the next several years as we continue our research and development efforts, advance our drug candidates through preclinical and clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization.
Prior to our initial public offering, or IPO, we had funded our operations primarily from the issuance and sale of convertible preferred stock and convertible promissory notes. In May 2018, we completed our IPO pursuant to which we issued 5,000,000 shares of our common stock at a price of $17.00 per share. We received net proceeds of $76.1 million from the IPO.
We do not expect to generate revenue from any drug candidates that we develop until we obtain regulatory approval for one or more of such drug candidates and commercialize our products or enter into collaborative agreements with third parties. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. As a result, we will need to raise additional capital. If sufficient funds on acceptable terms are not available when needed, we could be required to significantly reduce our operating expenses and delay, reduce the scope of, or eliminate one or more of our development programs.
We rely on third parties in the conduct of our preclinical studies and clinical trials and for manufacturing and supply of our drug candidates. We have no internal manufacturing capabilities, and we will continue to rely on third parties, many of whom are single-source suppliers, for our preclinical and clinical trial materials, as well as the commercial supply of our products. In addition, we do not yet have a marketing or sales organization or commercial infrastructure. Accordingly, we will incur significant expenses to develop a marketing and sales organization and commercial infrastructure in advance of generating any product sales.
facilities and other allocated expenses, including expenses for rent and facilities maintenance, and depreciation and amortization.
We expect our research and development expenses to increase substantially in the future as we advance our drug candidates into and through preclinical and clinical trials and pursue regulatory approval of our drug candidates. The process of conducting the necessary clinical trials to obtain regulatory approval is costly and time-consuming. Clinical trials generally become larger and more costly to conduct as they advance into later stages and, in the future, we will be required to make estimates for expense accruals related to clinical trial expenses. The actual probability of success for our drug candidates may be affected by a variety of factors including: the safety and efficacy of our drug candidates, early clinical data, investment in our clinical program, the ability of collaborators, if any, to successfully develop any drug candidates we license to them, competition, manufacturing capability and commercial viability. We may never succeed in achieving regulatory approval for any of our drug candidates. Due to the early-stage nature of our lead programs, we do not track costs on a project-by-project basis. As our programs enter clinical studies, we intend to track the cost of each program. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our drug candidates.
Our general and administrative expenses consist primarily of personnel costs, allocated facilities costs and other expenses for outside professional services, including legal, audit and accounting services, and depreciation and amortization expense related to property and equipment. Personnel costs consist of salaries, benefits and stock-based compensation. We expect to incur additional expenses associated with operating as a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission and standards applicable to companies listed on a national securities exchange, additional insurance expenses, investor relations activities and other administrative and professional services. We also expect to increase the size of our administrative headcount to support the growth of our business and operate as a public company.
Interest income is primarily related to interest earned on our marketable securities for the three months ended March 31, 2018 and 2017.


That's such a fun topic for the linky party. Super cute card, too. Perfect for teens. Love all the text on top and the great use of the negative circle.
ooo very fun!! and adorable card.
So fun, perfect for guys!
Perfect!! Love the bright colors and the design. This is great!


text:
Display Ad & Web Ad Information
IE Contact Information
IE Customer Payment
IE Monthly Music Calendar
IE Music Classifieds
Classified Advertising Information
IE Studio Guide – 2015 Edition
Illinois Entertainer
Chicagoland's Free Music Monthly Magazine – In Print And Online
IE Rewind
Around Hear
Caught In A Mosh
Studiophile
IE Digital Edition
IE Photo Gallery
Advertiser Message
Stage Buzz
7th Heaven interview
ilentertainer | August 31, 2010	| 2 Comments
25 years, 700 songs
Richie Hoffher has sacrificed for his band. "Man, I lived with my parents 'til I was 35." In between those rare nights sleeping in his own bed, Hoffher, the co-founder/guitarist, reinvested nearly every dollar he earned back into his band, 7th Heaven, playing over 250 gigs a year, sleeping on friends' floors, fleabag motels, and the occasional Motel 6 when a promoter offered an upgrade.
Today, Hoffher's reinvestment seems to have paid some dividends as we sit in his nearly new west suburban recording studio/home/NTD Records office along with long-time 7H guitarist/vocalist Nick Cox. Scattered over two floors of space, there are dozens of boxes of touring t-shirts and other swag, hundreds of packets of guitar strings, and more guitar picks than most bands would use in 10 years. "We're Dunlop's [pick manufacturer] biggest customer, bigger than Metallica. Our fans call us 'the band with the picks,'" says Hoffher
"I've been doing this since I was 15, this is always what I planned, to have a band and a label." Though Hoffher gives a passing nod to some of Chicago indie-label owners of days gone by like Jim Nash (Wax Trax) and Kai Dohm (Rotz Records), his business model, intended or not for NTD Records is not only a full-time promotional vehicle for "friends of the owner," but instead of industrial and punk rock on their label, NTD focuses like-minded suburban-based rock bands like Hi-Fi Superstar, He Said, She Said, and Men From Marz. Like a Stateside version of Alan McGee (former Oasis manager, label owner), Hoffher books, records, and promotes the bands on his label. "It just seemed as a natural progression as we booked 7th Heaven we needed opening bands and headliners on nights we could not commit to a certain venue."
"We've tried to mold our band and label in ways that means we'll always remain profitable, and that means avoiding some of the financial mistakes that other [now defunct] Chicago bands might have made, like Dovetail Joint and Extra Very." Cox and Hoffher note that those bands signed major-label deals with relatively large cash advances, while 7H decided to remain independent and release their own music. "We just decided that being signed to a label deal wouldn't work for us if it meant ending up in bankruptcy, which some of these bands did. We actually chose Plan B," Cox says.
7th Heaven began as a fair-to-middling, struggling hard-rock band in 1985 that learned to write songs the hard way, and that meant getting through the fog of not only being teenagers and writing some shaky material, a few tracks of which are being re-recorded and given new life for their Jukebox box set, but simply learning to be better songwriters and a live band. Their music has progressed in 25 years from '80s hair band mayhem to Nitzer Ebb-styled aggro-rock to its current incarnation as harmony-filled AOR, where Train meets Def Leppard. The return of Cox on guitar after a sabbatical, Mark Kennetz on bass, and co-founder Michael Mooshey on drums, has added to their continued stability.
The band has decidedly come into its own in the last five years with the addition of "Pop-Idol U.K." contestant Keith Semple, whose musical instincts complement Hoffher's honed rock and pop songwriting abilities. When former vocalist Andrew Blake departed the band on somewhat strained terms ("Unfortunately, he's the only former member I don't speak to any longer," says Hoffher), the band found Semple on Myspace and Hoffher e-mailed him on a whim. He was stunned when Stemple responded with a late-night phone call from Northern Ireland. After some negotiation, visas were obtained, the band flew him into O'Hare, and Semple became the band's third lead vocalist in 20 years. "It was really a longshot, I knew the landsape of vocalists around Chicago, but I wanted something different. I've always been fascinated by good singers. This band plays a lot of shows, and we needed someone with endurance, someone who wasn't afraid to perform in front of 10,0000 people, the guy who had the voice. That turned out to be Keith. This guy from Northern Ireland."
— John Vernon
To find out how it turned out, grab the September issue of Illinois Entertainer, available free throughout Chicagoland.
Category: Features, Monthly
Good Story. I remember seeing these guys when I was in college at ISU. Hard to believe they 've been together 25 years.
Hey 7H – I need some picks for my
"sister." Hee hee. When are you guys playing the Fuel Room again?
« File: September 2010
Xavier Rudd & Izintaba interview »
Click the cover to view this month's Digital Edition.
Stage Buzz: Tedeschi Trucks at Chicago Theatre
Stage Buzz: Hey Nonny's Winter Blues Summit
Stage Buzz: Signal The Launch at House of Blues
Hello My Name Is…Michael Des Barres
Media – January 2020
CJ on Cover Story: Depeche Mode
Blues Festival Guide Magazine and Online Directory of Blues Festivals Hey Nonny's Winter Blues Summit Jan 31-Feb 2 - Blues Festival Guide Magazine and Online Directory of Blues Festivals on Stage Buzz: Hey Nonny's Winter Blues Summit
Robservations: WBBM Newsradio promotes Jennifer Keiper, Andy Dahn - Robert Feder on Media – January 2020
Jeff Elbel on Cover Story – Liam Gallagher
Samuraiprincess on Cover Story – Liam Gallagher
IE.com Archive
© 2020 Illinois Entertainer. All rights reserved. Theme by Solostream.

redpajama_set_name: RedPajamaCommonCrawl


We are continuing our discussion about the religions in China.
And today we'll speak about Confucianism, Confucianism in China.
Confucianism became a symbol of China, of Chinese nation, and Confucius.
and many other countries which were affected by the Confucian's tradition.
When someone starts to speak about China, he or she usually mentioned Confucius.
So, Confucius, it's a sign of China.
It's a trademark of China and today, almost everyone in this world knows about Confucius.
about the symbolism of Confucius, this great sage that lived in ancient China.
There are a lot of questions about Confucianism.
it's a way that was taught by Confucius, this sage in ancient China.
that arrived from different teachers and different streams but was embodied by Confucius.
So, that's his personal teaching.
Another point that Confucianism, it's a way of the society.
and finally became a moral regulations, questions about the moral conduct of Chinese.
and Confucianism is the development of this teaching in traditional China.
So originally, the private teaching of Confucius was not like a more than Confucianism.
Confucianism, the teaching of the sage, Confucius, was not ever large teaching.
It was based on the very traditional norms such filial piety or the harmony.
So it was the teaching of one people for his followers and for his students.
Today, Confucianism it's much larger.
the national identity or national mentality in China.
So, in the larger sense, Confucianism is a national mentality of China.
There is a discussion about the religious nature of Confucianism.
Confucianism is mainly philosophical teaching so we call Confucianism as a philosophy.
and these religions put a much emphasis on the moral competence.
there were not a big difference between religions and philosophy.
So, religions and philosophy, or I call it teaching or dogma, jiao.
and moral tradition of the moral education and also, a religious tradition.
and philosophical content of the Confucius teaching.
that we can find in Confucianism, as well as, the many other religions in China.
First of all, how Confucianists call themselves.
The most widely known notion, it's Ru jiao.
Ru jiao are the teaching of the officials.
Or Kong jiao, the teaching of Confucius.
Both notions used at the same way.
as the followers of the Confucian tradition.
So, that's why the religion of Confucius was called the religion of officials.
Another very important point and very important notion in Confucius tradition is harmony.
Harmony, it means that the unity of everyone inside one society.
the equality between different sides and different dimensions of one society.
So, the most important thing for Confucians even today, it's a social harmony.
approach, and ideas embodied, for example, development of the country.
The main problem is how to find this social harmony among them.
and more stable became one of the main idea of Confucius and his followers.
So another point is the development of the idea of harmony.
It's the idea, great community, da tong.
we can reach this da tong and in this way to stabilize and to harmonize the society.
or the state of idea, it's how to find these point of balance.
of the society between different individuals in the society.
and administrative teaching of ancient and traditional China.
What was the idea for Confucianism?
the idealistic point of view was point of view to the society of ancient time.
The main idea was that the golden time, the golden age of China lays behind.
and just to reproduce this tradition in the present day time.
So, it means that Confucianism was mainly directed to the history.
And that's why history became so important for China.
of the rules of the sages of the past.
and other great sages which became the examples of the right behavior for Confucius.
that we cannot find any monasteries or temples in Confucianism.
or nuns in Confucian traditions.
But, we can find a lot of so-called academies, shuyuan in Chinese.
or we can call them universities for future Confucius officials.
and many sponsored by the state.
Another group of academy was sponsored by the private officials.
of the future development of China.
or academies, and these academies were not monasteries, were not temples.
or maybe the one of the most famous became is called the Guozi lan.
more than 50,000 successful candidates.
just near the very famous Shaolin Monastery, we can find a so called the Shuyuan.
It means the Academy of the Mountains.
one of the central of the Confucius training in the Ming Dynasty.
or actually it's a shrine or kong miao.
and sometimes to the ancestors or some family who build this kind of kong miao.
This kong miao by its architecture produce maybe Taoist temples or vice versa.
with the incense burning, with different kind of deities in several halls.
So it's, once again, it's a shrine but not a monastery.
as we compared with Buddhism or Taoism.


The Burlington Edwardian 51cm Cloakroom Basin with Basin Stand has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Victorian 560mm Basin with Basin Stand has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Victorian 610mm Basin with Basin Stand has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Edwardian Round 560mm Basin with Basin Stand has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Contemporary Basin with Basin Stand has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Edwardian 560mm Basin with Regal Stand has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Edwardian 610mm Basin with Basin Stand has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Edwardian Round 560mm Basin with Regal Stand has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Victorian 560mm Basin with Regal Stand has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Small Roll Top Basin with Stainless Steel Stand has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Edwardian 800mm Basin with Basin Stand has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Classic 650mm Basin with Chrome Basin Stand has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Classic 650mm Basin with Invisible Overflow & White Aluminium Stand has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Carrera Marble Top and Basin with Basin Stand has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Carrera Marble Top and Basin with Polished Aluminium Washstand has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Carrera Marble Top and Basin with White Aluminium Washstand has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Carrera Marble Top and Basin with Polished Aluminium Washstand with Shelf has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.
The Burlington Carrera Marble Top and Basin with White Aluminium Washstand with Shelf has a traditional appearance, lovingly crafted and hand finished with exceptional care using the finest materials and manufacturing processes.


SYLVANIA - Kaitlyn Dickey collected 12 points and 13 rebounds to help Effingham County (2-1) defeat host Screven County 61-38 on Saturday.
Whitney Roberson contributed 14 points and six steals.
Evans 2, Hicklen 4, Kaitlyn Dickey 12, Whitney Roberson 14, Stone 3, Hall 8, Cope 3, C. Usher 2, Boston 6, Smith 7.
Austin 7, Felton 6, White 4, Burns 1, Bria Lonan 20.
Shara Davis scored 25 to lead three players in double figures as Glynn Academy spoiled Jenkins' season and home opener.
Shara Davis 25, Roberts 4, McDonald 6, Reed 5, Sequoya Aldridge 13, Smiley 2, Jaquetta Wilkerson 10, Rose 9, Wallace 2, Hines 4, Lewis 6.
Camille Dash 14, Perrett 3, Gatling 4, Davis 1, Brown 2, Goodgame 8, Sydnee Bush 11, Corey Edwards 13.


text:
Days after fatal crash near Belfair, another crash at same spot
It was the same spot where, four days before, an 86-year-old man died after crossing the centerline and striking an oncoming vehicle.
Four days after a man was killed in a head-on crash outside Belfair, another man was injured Friday in a head-on crash at almost the exact same spot.
On Dec. 9 a 67-year-old Belfair man, suspected of being intoxicated, was driving the wrong way in the westbound lane of North Shore Road approaching Sand Hill Road at about 3 p.m. in a 2005 Subaru Outback, when he struck an oncoming Ford F-350, according to the Washington State Patrol.
The Belfair man was taken to St. Michael's Medical Center in Silverdale for treatment. The man driving the F-350 was not injured.
On Monday Dec. 5, 86-year-old Karl E. McNeill, of Belfair, was driving west on the road at about 1:12 p.m. when he crossed the centerline and struck an oncoming vehicle near Sand Hill Road.
Kitsap prosecutors back away from murder charges for 3 in 2005 killing Man arrested after he scales 40-story Chase Tower in downtown Phoenix A young man with autism has lived for months in a Reno hospital. He's not sick. He has nowhere else to go Some say Colorado Gov. Jared Polis is putting pressure to change wolf plan: What we know Super Bloom begins: Walker Canyon poppy fields closed as safety precaution


The Company has paid special attention to ensure that the information included on this Website will be updated and accurate. However, the Company does not guarantee or accept any responsibility for the appropriateness and accuracy of the content of this Website unless specifically and expressly stated otherwise.
Additionally, please approve of the fact that the content or URL of this Website may be changed, or suspended, or the operation thereof ceased, without prior notice. Regardless of reason, the Company does not assume responsibility for any damages arising from changes to the content of this Website or from suspension or cessation of the operation.
In addition to the previous Clause, please note the "IR Related Disclaimers".


The new rules for Reg D solicitation are a step in the wrong direction. Over a year ago, Congress made it clear, via a new law, to make private investing more accessible, not less. That law included a provision to make solicitation possible, not to punish entrepreneurs for raising funding.
The one year "penalty box" is egregious. Remove that from the proposed rules.
The pre-filed Form D serves no market function. Investors are not going to search Edgar for that filing, vs. reading the already expected PPMs, term sheets, etc.
Filing any Form D or other form stating that soliciation will take place via a web site, via a specific Angel group, via specific industry events also serve no market function. Investors do not care if an entrepreneur has notified the SEC of an advertisement, they only care what is in that advertisement.
If you want to protect investors, then provide them an easy path to complain to the SEC of fraud. Let the SEC sue those companies that are committing fraud. Let the courts throw those entrepreneurs in jail and fine them and punish them well beyond a one year "penalty box".
The existing no soliciation is a better set of rules than what the SEC is proposing for solicitation. Please forget this proposal and try again. This time from the shoes of the investors, rather than what is easiest for the regulators.


Hawaiian Shaved Ice black cherry snow cone syrup offers the taste of actual black cherries that you love. This real fruit taste is the perfect addition to any snow cone. This delicious shaved ice has the tart flavor of a sour black cherry. Kids and adults love this flavor because of the real cherry taste. Your family will probably have a hard time deciding whether or not this is from an actual black cherry!
Whether this treat is for your next party or just a night with the kids, black cherry shaved ice syrup will not disappoint. Purchase this flavor in the gallon size so there is plenty for the whole party to enjoy. We also have black cherry flavored syrup available in the gallon size for a smaller group to share, or in the assorted packages so that you can enjoy some of our other great, fruity flavors!


text:
Q: How to understand the results of nonlinear mixed-effects regression model I have some data, obtained from 4 different groups. Each repeat is some 4 parametric sigmoid. I need to fit the data to sigmoidal function and answer the question, whether sigmoids are different between groups. I wrote the following code (MatLab):
%% simulate data
% define parameters for each group
P = [[0 2500 -10 -0.2]; % grou1
    [-10 2000 -20 0];   % group2
    [100 1500 -1 0.1];  % group3
    [10 600 -5 -0.3]];  % group4
% simulate data
fnSigma = @(p,x) p(1) + (p(2)-p(1))./(1+exp(-p(3).*(x-p(4))));
grp = [];
Curves = [];
x = linspace(-1,1,20);
for iRep = 1:10
    for iGroup = 1:4
        Curves = [Curves;(fnSigma(P(iGroup,:),x)+normrnd(0,10,1,20))];
        grp = [grp;iGroup];
    end
end
% fit a nonlinear mixed-effects regression model
X = repmat(x,40,1);
G = repmat(grp,1,20);
P0 = mean(P);
[beta1,PSI1,stats1] = nlmefit(X(:),Curves(:),G(:),[],fnSigma,P0);

the problem is I do not understand the output:
beta1 =

   1.0e+03 *

   -0.0000
    1.6600
   -0.0089
   -0.0001

PSI1 =

   1.0e+05 *

    0.0006         0         0         0
         0    4.9275         0         0
         0         0    0.0005         0
         0         0         0    0.0000

stats1 =

 struct with fields:

       dfe: 791
      logl: -3.0316e+03
       mse: 95.6008
      rmse: 9.7410
errorparam: 9.7776
       aic: 6.0813e+03
       bic: 6.0758e+03
      covb: [4×4 double]
    sebeta: [4.5810 351.0160 3.5396 0.0948]
      ires: [800×1 double]
      pres: [800×1 double]
     iwres: [800×1 double]
     pwres: [800×1 double]
     cwres: [800×1 double]

Could you educate me and explain what does this output means?

redpajama_set_name: RedPajamaStackExchange


Grief is hard. Grief is messy. And, grief feels lonely.
Grief 101: A Support Group for Students is a 5 week support group focused on Grief and Loss for University of Saskatchewan students. This group will be faciliated by Lisa Greig, Intake Counsellor with Student Affairs and Outreach Services. The dates and corresponding themes are outlined below. Please join Lisa and other students in a safe and supportive environment.
- Grief 101: A Support Group for Students Eventbrite.


text:
Christmas TV Movies 2013
Ready or not, it's that time of year again! Readers frequently ask me when Christmas TV programming begins and they are usually surprised by my answer--the day after Halloween. To be more accurate, Christmas TV programming airs year round. In fact, every single day, 365 days a year, there are typically multiple Christmas-themed episodes and theatrical release movies to choose from that air throughout the TV networks' daily schedules. I follow these Christmas listings fairly closely and make suggestions on the best of these listings--or at least the most interesting, and most rare ones--in two places. You are welcome to follow my suggestions, "SET YOUR DVRs....," on my facebook page Tis the Season TV and also on twitter, @TistheSeasonTV.
However, now is that special time of year when the TV networks begin to premiere their NEW Christmas TV movies as well as open up their schedules to re-broadcast their older Christmas TV movies. It's exciting, isn't it? Let me guide you toward finding the new Christmas TV movies, as well as where to find older favorites airing in the TV listings.
Christmas TV movies can usually be found in a few places--please review my post from last summer entitled Where to Watch Christmas Movies on TV. Don't forget to note the difference between theatrical release movies and made-for-TV movies.
You may have noticed that the Hallmark Channel has already begun airing their Christmas TV movies. They typically begin airing Christmas TV movies the week after Halloween. They have already begun airing older Hallmark original Christmas TV movies from their archives and will continue this each day in November--and December. This year, Hallmark Channel will premiere its first new Christmas TV movie on Friday, Nov. 8th--entitled Pete's Christmas--and the premieres will continue to roll out every weekend through November and into mid-December on Saturdays and Sundays at 8pm(ET). Hallmark Channel is debuting twelve new movies in the 2013 season alone. Check out this link to the Hallmark Channel website learn more about these new titles.
Don't overlook the Hallmark Movie Channel. They begin airing older Christmas TV movies starting Monday, November 11th with all-day marathons. (The all-day marathons of Christmas movies continue each weekday--and exclude Saturdays and Sundays through November). This may be the schedule to watch if you're looking to re-watch an older favorite movie. Skimming the titles, I see rare TV movies airing such as Angel of Pennsylvania Avenue (with Robert Urich), and The Night They Saved Christmas (with Jaclyn Smith and Art Carney), as well as older theatrical release movies such as Holiday Affair (starring Robert Mitchum and Janet Leigh), It Happened on 5th Avenue, Christmas in Connecticut (with Barbara Stanwyck), and more. Hallmark Movie Channel is also premiering the new Christmas TV movie Christmas with Tucker, a prequel to the much-beloved TV movie A Dog Named Christmas, on Monday Nov. 25th at 9pm(ET).
One new Christmas TV movie in 2013 is A Country Christmas Story debuting on Lifetime.
Lifetime begins airing older Christmas TV movies starting Wednesday, Nov. 6th. According to their November schedule, you can watch at least one Christmas movie each day throughout the month! That's exciting! Lifetime will premiere their first of seven new Christmas TV movies on Saturday, Nov. 9th at 8pm(ET) entitled A Country Christmas Story--starring Dolly Parton, Brian McKnight, and Mary Kay Place. I can't wait!
If you also watch Lifetime Movie Network (LMN), you'll want to check out their schedules as well. Every Thursday in November--except Thanksgiving Day (Nov. 28th)--they are running all-day marathons of older Christmas TV movies.
The newly named UP network (formerly known as Gospel Music Channel-GMC) is another place to find new Christmas TV movies as well as older favorites. According to this press release, their Christmas programming begins Monday, Nov. 18th. They are also premiering six new Christmas TV movies in 2013. Their first new Christmas TV movie is 3 Day Christmas starring George Newbern and Corbin Bernsen debuting Friday Nov. 22nd, at 9pm(ET). I'm also excited to say that their press release reveals they will be re-airing one of my all-time favorite Christmas TV movies, 1971's The Homecoming: A Christmas Story--the movie that sparked the TV series The Waltons.
Another major source of holiday entertainment is ABC Family channel and their 25 Days of Christmas scheduling (December holiday programming) as well as their Countdown to 25 Days of Christmas (November holiday programming). Remember the downloadable 25 Days of Christmas schedule is only the highlights! They actually air more programming during the non-listed hours. (I always check the network's on-line TV listings to know what they are broadcasting 24 hours a day). ABC Family Channel will debut two new Christmas TV movies this season. The first debut is Tuesday Nov. 26th at 7pm(ET) entitled Christmas Bounty starring Mike "the Miz" Mizanin from the WWE. The Countdown to the 25 Days of Christmas begins Wednesday, Nov. 20th.
This year will also bring a new Christmas TV movie from the Hallmark Hall of Fame, the critically-acclaimed TV movie series. On December 1st at 9pm(ET), the ABC network will air Christmas in Conway starring Andy Garcia, Mandy Moore, and Mary Louise Parker.
I also expect to see holiday listings eventually released by Ion network. According to a third party press releases, Ion is premiering five new Christmas TV movies in 2013 to air alongside their growing number of Christmas movies from past years.
Hold on to your hats, this year is proving to be another bumper year for Christmas movie premieres.
Wings1295 November 2, 2013 at 7:49 PM
Holy cow, that is a lot of new movies in addition to all the older offerings! In a few years, there is going to be enough to air a different movie every day - heck every two hours - from Halloween to Christmas! Not that I am complaining. :)
Joanna November 3, 2013 at 6:03 PM
Every year the networks get more viewers for their Christmas TV movies. I think we'll continue to see expanding listings.
asfaf
Mia September 15, 2018 at 5:21 AM
Marketing (SEO) July 6, 2019 at 3:36 AM
Maybe you are aware that anyone is now possible to watch all their favorite movies online without having to worry about running out to the local video store just to pick up one of the Hollywood Blockbusters. Well with todays technology anyone can now watch movies from home. However how can the person who knows absolutely nothing koktale these sites and with all the information online figure out how to pick the best movie membership site?
Marketing (SEO) July 11, 2019 at 6:25 AM
A blog like yours should online singing audition form earning much money from adsense.'~::-
Waltons Christmas Recap
Christmas TV Specials 2013
Live Tweeting Christmas TV Party
Upcoming Events--2013
Classic TV Blog Association--2013 Recap
Sherlock Holmes Christmas (1968)
Knight Rider Christmas (1983)
Ideal Christmas Eve Line-Up (2013)
Full House Christmas (1988)
Christmas Comes to Willow Creek (1987)


text:
Javed, a British teen of Pakistani descent, is growing up in England in 1987. Amidst the racial and economic turmoil of the times, he writes poetry as a means to escape the intolerance of his hometown and the inflexibility of his traditional father. But when he is introduced to the music of 'the Boss,' Javed sees parallels to his working-class life in Springsteen's powerful lyrics.
Publisher: [United States] :, Warner Bros. Entertainment,, [2019]
Branch Call Number: BLI
Characteristics: v
digital, optical, surround, Dolby Digital 5.1 DVS, rda
video file, DVD video, region 1, rda
Additional Contributors: Atwell, Hayley 1982-
Brydon, Rob 1965-
Chadha, Gurinder
Chapman, Dean-Charles 1997-
Ghir, Kulvinder
Kalra, Viveik
Manzoor, Sarfraz 1971-
Phagura, Aaron
Williams, Nell
Read more reviews of Blinded by the Light at iDreamBooks.com
SPL_Liz Jan 07, 2020
I didn't know I needed a feel good movie about Bruce Springsteen but, here we are.
ArapahoeSarah Dec 20, 2019
A heartwarming, feel-good film that underscores the universality of music. If you liked "Yesterday" or "Bend it Like Beckham," then you may also enjoy this film.
winston16 Dec 16, 2019
Enjoyed it-- a lot like the director's Bend It Like Beckam only with a teen boy this time and music as the wedge between generations. Bruce S was obviously on board which is fun.
SAPL454 Dec 06, 2019
Truly a tale of love and compassion between Javed Kahn, his family and Bruce Springsteen!
jfd5 Dec 05, 2019
Wonderful story. An unexpected gem. Really enjoyable movie, suitable for all ages. Extra special when based on true story.
DazzlingMoonlight Dec 03, 2019
A great story with great actors and great songs! Blinded by the Light is a reminder that music in whatever genre speaks to all people equally.
ReadingintheCorner Nov 25, 2019
This movie has great music and really rings true about what it's like to be a music fan.
Rock Music — Drama
Pakistanis — Great Britain — Drama
Teenagers — Great Britain — Drama
Great Britain — Race Relations — 20th Century — Drama


Sending a trio of red balloons out into the universe, Mr Mustard and little Doris watch as they float towards the sky, hoping their wishes come true! They won't tell us what they are but we have a sneaky feeling that the miniature Jack Russell's involves bones. If you're wishing and praying for more fantastic Sam Toft masterpieces then look no further, because this delightful canvas print has all the usual magic and enchantment this Brighton based artist is renowned for.
High quality, framed Make a Wish, Sam Toft canvas print with a bespoke frame by our custom framing service.


text:
Do pelnego funkcjonowania witryny potrzebny jest JavaScript.
This page needs JavaScript activated to work properly.
Advertising films
Buttermilk, sour milk
UHT Cream
Sweet cheese
Cheese, yellow
Butter in blocks
Yoghurts
Career/ announcements
OSM Radomsko – headquarters
Dairy Factory in Nowy Targ
Wholesale and retail outlets network
Ta strona wykorzystuje pliki cookies do poprawnego funkcjonowania. Więcej informacji znajdziesz w naszej polityce cookies.
The beginnings of the existence of dairy cooperatives on the Radomsko land date back to the turn of the 19th and 20th centuries. The first Cooperative was Włościańska Spółdzielnia Mleczarska, founded around 1904, at a distance of 9 km. from Radomsko Woźniki. The Radomsko district was at that time an exceptionally agricultural area, and so many small dairies and branches were established in the neighboring villages, which merged into larger cooperatives.
The operations of Okręgowa Mleczarnia Spółdzielcza, today's District Dairy Cooperative in Radomsko, are dated from the 30s of the last century. Archival materials state that initially it acted as a central actively organizing transport and metastasis of raw material in the field, created a commercial network of stores with dairy products, milk sales points, egg collections, mediated in obtaining loans and in purchases necessary to produce funds for scattered small areas, rural cooperatives and branches, remained in close cooperation with the Union of Dairy Cooperatives and Eggs and Farm Chambers.
In 1935, the land on which the processing plant was established was purchased in Radomsko. The number of milk suppliers grew very quickly and along with it the development of the Cooperative. Warfare and difficult occupation years stopped this process, but they did not stop the Cooperative. Production costs increased day by day, the raw material was obtained very irregularly and with great difficulty, and yet the Radomszcz cooperatives sacrificed assistance to others degraded during the war to the dairies, and members and suppliers of milk and workers supplied the necessary rationed goods on the farm: coal, kerosene, etc.
The first years of post-war reality did not create the Cooperative's conditions for getting out of the crisis. Despite the introduction of forced milk supplies, production was difficult to conduct on a scheduled basis. The costs were high, while the prices of dairy products were set low. Added to this was the interference of the then authorities in production and commercial matters and the enforcing of economically unjustified decisions.
In 1950, like all cooperatives in the country, the District Dairy Cooperative in Radomsko, because it sounded its post-war name, was nationalized. A Poviat Dairy Enterprise Przedsiębiorstwo Państwowe in Radomsko was established, which survived only 7 years, because another act reactivated cooperatives restoring them assets and former identity.
From 1946, for almost 40 years, the position of the President of the Management Board was held by Franciszek Jeziorski, who deserved the land of Radomsko as both a member of the Sejm for two terms in the 1960s and as an activist for the development of dairy cooperatives and the entire peasant movement. It was thanks to his efforts that the central authorities gave their consent and granted funds for the construction in Radomsko, in 1973, of an Italian milk powder company, whose formation initiated the continuing development of the Cooperative until today.
Since 1985, the continuing good traditions of his predecessor has been the current President of the Board, Eng. Andrzej Chodkowski, whose decisions and personal involvement caused that the Cooperative not only overcame the economic crisis in the years of political and economic transformation, but also established its significant position in the conditions of a competitive free market.
In the 1980s, a butter plant was located next to the powdered milk, 10 years later a modern gas boiler room and a department of dairy fancy goods that met European standards. 1996-2007 is a continuous modernization of the plant and modernization of technology and further dynamic development of the Cooperative. In 2005, our Cooperative was enriched with the Dairy Production Plant in Nowy Targ, where a modern cheese factory producing Dutch cheese was launched. OSM in Radomsko currently has 3800 cooperatives and employs 560 people.
As a result of all these activities, the Cooperative is today one of the leading dairy companies in the country in terms of the amount of milk purchased, the value of revenues, profitability and investment outlays.
© Copyright 2018 Radomsko.Privacy policy © 2018 WebsiteStyle.pl - Strony Internetowe